Home>Topics>Stocks>Theravance

Theravance THRX

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Anoro Ellipta launch in Japan triggers milestone payment

      Headlines

      Thu, 4 Sep 2014

      launches bronchodilator treatment Anoro Ellipta ( umeclidinium/vilanterol ) triggering a $10M milestone payment from Theravance ( THRX -0.2% ) to Glaxo. The two companies entered into a collaboration agreement in 2002 to develop the product

    2. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      21.5% of assets are invested in small- and mid-cap pharmaceutical firms such as Mylan MYL, Salix SLXP, and Theravance THRX . (This ETF holds Nasdaq-listed firms only, and the U.S.' largest pharmaceutical firms trade on the New York

    3. Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market

      Headlines

      Thu, 21 Aug 2014

      By Virginia Value Investor : Theravance (NASDAQ: THRX ) is probably a familiar name ..... re not familiar with it, Theravance is a biopharmaceutical company ..... NYSE: GSK ). On June 2nd, Theravance completed a spin separating

    4. Positive Ad Comm vote for BI COPD drug

      Headlines

      Thu, 14 Aug 2014

      tiotropium bromide inhalation spray for the treatment of bronchospasms in patients with chronic obstructive pulmonary disease (COPD). Related tickers: ( GSK +0.6% ) ( THRX -1.4% ) ( NVS +0.7% ) ( AZN +0.1% ) Post your comment!

    5. Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?

      Headlines

      Thu, 14 Aug 2014

      By Jim Bowie : Typical antibiotic regimes for treating Acute Bacterial Skin and Skin Structure Infections ("ABSSSI") have run about 7 - 14 days and often include twice daily infusions to treat serious infections. These long-winded treatments ultimately support the buildup of resistance as bacteria

    6. Theravance Biopharma reports Q2 loss

      Headlines

      Wed, 13 Aug 2014

      Theravance Biopharma (NASDAQ: TBPH ): Q2 EPS of -$1.83. Revenue of $3M. Press Release Post your comment!

    7. Theravance Biopharma Q2 results

      Headlines

      Wed, 13 Aug 2014

      Theravance Biopharma ( TBPH +2.6% ) Q2 results : Revenues: $3.0M (+999%); Operating Expenses: $59.4M (+52.3%); Net

    8. Update: Theravance Reports Increased Patient Access And High Confidence In Dividend

      Headlines

      Thu, 7 Aug 2014

      By Early Retiree : Yesterday, Theravance (NASDAQ: THRX ) released its Q2 earnings update. Being still in the ..... which was the first without Biopharma (NASDAQ: TBPH ). Theravance has $369 million of cash, which cover its announced

    9. Theravance's ( THRX ) CEO Rick Winningham on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 7 Aug 2014

      Theravance , Inc. (NASDAQ: THRX ) Q2 2014 Earnings Conference Call August 06, 2014 05:30 PM ET Executives ..... afternoon. At this time I would like to welcome everyone to the Theravance conference call. During the presentation all participants will

    10. Theravance declares $0.25 dividend

      Headlines

      Wed, 6 Aug 2014

      Theravance , (NASDAQ: THRX ) declares $0.25/share quarterly dividend . Payable Sept. 18; for shareholders of record Aug. 28; ex-div Aug. 26. Post your comment!

    « Prev12345Next »
    Content Partners